Efficacy of Tocilizumab in Conventional Treatment-Refractory Adult-Onset Still's Disease

Autor: Ortiz-Sanjuan, F, Blanco, R, Calvo-Rio, V, Narvaez, J, Romero, ER, Olive, A, Castaneda, S, Flores, AG, Hernandez, MV, Mata, C, Vilamajo, IR, Giraldo, WAS, Caracuel, MA, Freire, M, Arango, CG, Llobet, J, Arija, SM, Marras, C, Moll-Tuduri, C, Plasencia-Rodriguez, C, Rosello, R, Urruticoechea, A, Velloso-Feijoo, ML, del Blanco, J, Gonzalez-Vela, MC, Rueda-Gotor, J, Pina, T, Loricera, J, Gonzalez-Gay, MA

Publikováno v: Arthritis & Rheumatology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Objective. Adult-onset Still's disease (AOSD) is frequently refractory to standard therapy. Tocilizumab (TCZ) has demonstrated efficacy in single cases and in small series of patients with AOSD. The aim of this multicenter study was to assess the eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::1713dfabd5d39ee3af3dc5a724ce1fd7
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=9261